119 related articles for article (PubMed ID: 26916347)
1. Supramolecular Probes for Assessing Glutamine Uptake Enable Semi-Quantitative Metabolic Models in Single Cells.
Xue M; Wei W; Su Y; Johnson D; Heath JR
J Am Chem Soc; 2016 Mar; 138(9):3085-93. PubMed ID: 26916347
[TBL] [Abstract][Full Text] [Related]
2. Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells.
Xue M; Wei W; Su Y; Kim J; Shin YS; Mai WX; Nathanson DA; Heath JR
J Am Chem Soc; 2015 Apr; 137(12):4066-9. PubMed ID: 25789560
[TBL] [Abstract][Full Text] [Related]
3. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Wykosky J; Hu J; Gomez GG; Taylor T; Villa GR; Pizzo D; VandenBerg SR; Thorne AH; Chen CC; Mischel PS; Gonias SL; Cavenee WK; Furnari FB
Cancer Res; 2015 Jan; 75(2):394-404. PubMed ID: 25432173
[TBL] [Abstract][Full Text] [Related]
4. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Zhao Q; Kretschmer N; Bauer R; Efferth T
Int J Cancer; 2015 Sep; 137(6):1446-56. PubMed ID: 25688715
[TBL] [Abstract][Full Text] [Related]
5. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Sundby E; Han J; Kaspersen SJ; Hoff BH
Eur J Pharm Sci; 2015 Dec; 80():56-65. PubMed ID: 26296860
[TBL] [Abstract][Full Text] [Related]
6. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
8. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
11. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
12. Metabolic therapy: a new paradigm for managing malignant brain cancer.
Seyfried TN; Flores R; Poff AM; D'Agostino DP; Mukherjee P
Cancer Lett; 2015 Jan; 356(2 Pt A):289-300. PubMed ID: 25069036
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
14. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
15. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.
Mellinghoff IK; Cloughesy TF; Mischel PS
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):378-81. PubMed ID: 17255257
[TBL] [Abstract][Full Text] [Related]
16. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
[TBL] [Abstract][Full Text] [Related]
17. Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling.
Oelmann E; Sreter L; Schuller I; Serve H; Koenigsmann M; Wiedenmann B; Oberberg D; Reufi B; Thiel E; Berdel WE
Cancer Res; 1995 May; 55(10):2212-9. PubMed ID: 7538048
[TBL] [Abstract][Full Text] [Related]
18. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
19. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
20. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
Liu LL; Li F; Pao W; Michor F
PLoS One; 2015; 10(11):e0141665. PubMed ID: 26536620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]